Posted on

Field Trip Health Ltd. Announces Opening of Field Trip Health Center in Atlanta, GA, as it Continues Expansion in the US

The Field Trip Health location in Atlanta is believed to be the first psychedelic-enhanced therapy center in the city

ATLANTA, Jan. 26, 2021 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (CSE: FTRP, OTCBB: FTRPF) (“Field Trip”), a global leader in the development and delivery of psychedelic therapies, announced today the opening of their fifth location in the United States in the city of Atlanta, GA, one of many locations that Field Trip is planning to open in 2021. Located in the Glenwood Park neighborhood, the Atlanta location is the first Field Trip Health center to open this year, following the opening of Toronto, New York, Los Angeles and Chicago in 2020.

With the opening of the Atlanta location, Field Trip continues to execute on its strategy to demonstrate the efficacy and safety of psychedelic-enhanced therapies to promote mental and emotional health and well-being across the country. Psychedelic-enhanced therapies have the potential to transform lives by treating such mental health challenges as depression, anxiety and PTSD, leading to improved well-being, optimism and increased neural plasticity according to multiple evidence-based studies from world-class institutions across the globe.

Field Trip’s step-by-step, integrated treatment programs are medically supervised and utilize ketamine (a legal, dissociative psychedelic molecule) in conjunction with psychotherapy, mindfulness, and self-care in a comfortable, spa-like environment to support those struggling with depression and other mental health challenges. Each Field Trip Health center is thoughtfully and intentionally designed to promote healing and provide people with a calming space before, during, and after treatment, and Atlanta is no different.

A great deal of consideration and thought goes into making each Field Trip Health center suited for the community it serves. The design of the Atlanta location was heavily influenced by the neighborhood and its building’s historic architecture. The decor is welcoming yet preserves the gothic-style heritage from the building, and there are nods to the local community throughout the space to give it an authentic Atlanta feeling.

Ronan Levy, Field Trip’s Executive Chairman added: “Psychedelic medicine is in the midst of a renaissance, experiencing renewed interest from the medical and scientific community around the world; in large part because of the capacity of psychedelic therapies to help people experience a sense of renewal and rebirth. With the Atlanta location that sense of a renewal and rebirth goes a step further. By being part of the redevelopment of the Atlanta Stockade, a former prison complex with a long and intricate history, our Atlanta location takes this narrative of renewal, rebirth and renaissance a step further. We are delighted to take a once penal building it and turn into a center for healing, expansion and growth.”

Dr. Ryan Yermus, Field Trip Health’s Chief Clinical Officer commented: “With the opening of our Atlanta location, we continue to deliver best-in-class psychedelic therapies to communities in the US. With each new Field Trip Health center, we not only create incredible impact and healing, we also advance the knowledge and application of psychedelic-assisted therapies. We are incredibly excited to bring this treatment to the people of Atlanta.”

The address for the Atlanta clinic is 750 Glenwood Avenue, SE Building 200, Suite 210, Atlanta, GA 30316 and patients can book a consultation by phone (1-888-519-6016), email (atlanta@fieldtriphealth.com) or online at https://www.fieldtriphealth.com/locations/atlanta.

About Field Trip Health Ltd.

Field Trip is the global leader in the development and delivery of psychedelic therapies, with three components, Field Trip Discovery, Field Trip Health, and Field Trip Digital. Field Trip Discovery is leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics, Field Trip Health clinics provide psychedelic-enhanced therapies, and Field Trip Digital is building the digital and technological tools to support psychedelic experiences and consciousness expansion. Field Trip helps people in the communities where we operate, allowing those seeking accelerated personal growth to use a simple, evidence-based approach to heal and heighten engagement with the world.

Learn more at https://www.fieldtriphealth.com and https://www.meetfieldtrip.com.

Follow us on Twitter and Instagram: @fieldtriphealth

To receive company updates about Field Trip and to be added to the email distribution list please sign up here.

For further information, contact Ronan Levy, Executive Chairman and a Director at Field Trip, at 1 (833) 833-1967.

Cautionary Note Regarding Forward-Looking Information.

This release includes forward-looking information within the meaning of Canadian securities laws regarding Field Trip and its business, which may include, but are not limited to, statements with respect to the listing of the common shares of Field Trip on the Canadian Securities Exchange, and the timing of such events. Often but not always, forward-looking information can be identified by the use of words such as “expect”, “intends”, “anticipated”, “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would” or “will” be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of Field Trip, and are based on assumptions and subject to risks and uncertainties. Although the management of Field Trip believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including risks regarding the COVID-19 epidemic, the medical clinic industry, market conditions, economic factors, management’s ability to manage and to operate the business and the equity markets generally. Although Field Trip has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Field Trip does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

The CSE, nor its Regulation Services Provider, has neither approved nor disapproved the contents of this news release.

Media contacts:
Rachel Moskowitz
Autumn Communications
202-276-7881
fieldtrip@autumncommunications.com

Investor contacts:
Elizabeth Barker
KCSA Strategic Communications
212-896-1203
ebarker@kcsa.com

SOURCE Field Trip Health Ltd.

Posted on

Core One Labs Announces Vocan Assembles Equipment to produce biosynthesized Psilocybin

Vancouver, British Columbia, Canada – January 23, 2021 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce its wholly-owned subsidiary Vocan Biotechnologies Inc. (“Vocan”) has assembled the necessary equipment, which will allow the laboratory to commence the process of recombinant production of psilocybin.  The process that engineers bacteria incorporating optimized biosynthetic genes from the Psilocybe cubensis mushroom, will enable the bacteria to act as a biological factory and synthesize psilocybin that is cost effective using simple building blocks.

Vocan’s platform can make the active compounds that occur naturally, by using a gene mimicry process and simple chemical modifications to enable the creation of bioidentical compounds as well as known and novel analogs.  The analog compounds could prove to be more effective, targeted and safer.

Vocan has now received and assembled equipment required to move forward on its plan to produce biosynthesized psilocybin. Due to the cost and long lead times, this is a critical milestone in the company’s plan. The equipment enables Vocan to improve on the current work being conducted in the lab and puts Vocan ahead of schedule on its plan to begin the recombinant production of psilocybin.

“Vocan’s recombinant production of psilocybin is a significant improvement over the current methods of psilocybin production. Reducing both the cost and time needed to produce and purify psilocybin to only a few days, compared to much longer and more expensive methods for whole mushroom extraction. Having the equipment purchased and assembled positions Vocan to execute on its objectives in the short term.” Stated Joel Shacker CEO of the Company.

Further to the Company’s press release dated January 15, 2021 announcing the closing of its sale of non-core assets, the Company wishes to correct that it has issued a total of 500,000 common shares as an administrative fee to three arms-length third-parties who assisted with facilitating such sale, not 350,000 shares to two parties, as previously announced.

About Core One Labs Inc.

Core One Labs Inc. is a biotechnology research and development company focused in life sciences and on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy.  The Company has developed a patent pending thin film oral strip (the “technology”) which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. With this technology, the Company intends to further develop its IP technology to focus on delivering psychedelic molecules with an initial focus on biosynthesized psilocybin. Core One also holds an interest in walk-in medical clinics which maintain a database of over 200,000 patients combined. Through research and development in these clinics, including the integration of its intellectual property related to psychedelic treatments and novel drug therapies, the Company intends to work towards regulatory approval for research that advances psychedelic-derived treatments for mental health disorders.

Core One Labs Inc.

Joel Shacker

Chief Executive Officer

FOR MORE INFORMATION, PLEASE CONTACT:

info@core1labs.com

1-866-347-5058

 

Cautionary Disclaimer Statement:

 

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

 

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, among other things: risks and uncertainties relating to the Company’s limited operating history and the need to comply with environmental and governmental regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information. In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription. Health Canada has not approved psilocybin as a drug for any indication. Core One Labs Inc. does not have any direct or indirect involvement with illegal selling, production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One Labs Inc. believes psychedelic substances can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics substances for recreational use. Core One Labs Inc. does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks.

Posted on

Mind Cure Health Inc. Announces an Increase to Previously Announced Bought Deal Public Offering

/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES./

VANCOUVER, BC, Jan. 22, 2021 /CNW/ – Mind Cure Health Inc. (“Mind Cure” or the “Company”) (CSE: MCUR), a mental health and wellness company with a mission to identify and develop products that ease suffering, increase productivity, and enhance mental health, is pleased to announce that it has entered into an amended agreement with a syndicate of underwriters led by Canaccord Genuity Corp. to increase the size of the previously announced bought deal financing. Pursuant to the amended terms, the Underwriters have agreed to purchase, on a bought deal basis, an aggregate of 33,334,000 units (the “Units”) of the Company at a price of C$0.60 per Unit (the “Offering Price”) for aggregate gross proceeds to the Company of approximately C$20 million (the “Offering”).

Each Unit shall consist of one common share (each a “Common Share”) and one-half of one common share purchase warrant of the Company (each whole common share purchase warrant, a “Warrant”). Each Warrant shall be exercisable to acquire one common share of the Company for a period of 60 months from closing of the transaction at an exercise price of C$0.80 per Warrant, subject to acceleration and adjustment in certain events.

The Company has granted the Underwriters an option (the “Over-Allotment Option”) to purchase up to an additional 5,000,100 Units at the Offering Price, exercisable at any time, for a period of 30 days following the closing of the Offering to cover over-allotments, if any, and for market stabilization purposes. In the event the Over-Allotment Option is exercised in full, the aggregate gross proceeds of the Offering will be approximately C$23 million.

If, at any time following the closing of the Offering, the daily volume weighted average trading price of the Common Shares on the Canadian Securities Exchange (the “CSE”) is greater than C$1.50 per Common Share for the preceding 10 consecutive trading days, the Company shall have the right to accelerate the expiry date of the Warrants to a date that is at least 30 trading days following the date of the Company issuing a press release disclosing such acceleration.

The Units will be offered by way of a short form prospectus to be filed in all provinces of Canada except Quebec. The Offering is expected to close on or about February 12, 2021 and is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the CSE and the applicable securities regulatory authorities.

The Company will use best efforts to obtain the necessary approvals to list the Common Shares, Warrants, and the Common Shares issuable upon exercise of the Warrants on the CSE.

The net proceeds of the Offering will be used by the Company for product research, development and expansion, to further the Company’s technological offerings and capabilities, including the build-out of its iSTRYM application and refinement of its bioinformatics statistical analysis platform PsyCollage, marketing expenditures related to company investor relations and product awareness, as well as working capital and general corporate purposes.

ON BEHALF OF THE BOARD OF MIND CURE HEALTH INC.
Kelsey Ramsden
President and Chief Executive Officer

About Mind Cure
Mind Cure Health Inc. (CSE:MCUR) exists as a response to the current mental health crisis and urgent calls for effective treatments. Mind Cure believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.

Mind Cure is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. Mind Cure is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

Forward Looking Statements

Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with

respect to: Mind Cure’s translational research program; Mind Cure’s work with psilocybin, ketamine and ibogaine; Mind Cure developing and optimizing drugs that treat pain; Mind Cure delivering validation of commercially viable medicines, methods and tools; Mind Cure building upon the current landscape of research in psychedelic compounds; Mind Cure’s research into pain; Mind Cure bringing treatment to market with speed and rigor. Forward-looking information is based on a number of key expectations and assumptions made by Mind Cure, including, without limitation: the COVID-19 pandemic impact on the Canadian and global economy and Mind Cure’s business, and the extent and duration of such impact; Mind Cure being able to research and develop optimized drugs that treat pain; Mind Cure being able to deliver validation of commercially viable medicines, methods and tools; Mind Cure being able to bring treatments to market. Although the forward-looking information contained in this news release is based upon what Mind Cure believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information. Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian and global economy, Mind Cure’s industry and its business, which may negatively impact, and may continue to negatively impact, Mind Cure and may materially adversely affect its investments, results of operations, financial condition and Mind Cure’s ability to obtain additional

equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; Mind Cure developing optimized drugs that treat physical and psychological pain. and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect Mind Cure can be found under “Risk Factors” in Mind Cure’s final prospectus which is available on SEDAR at www.sedar.com. The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to Mind Cure. The forward-looking information is stated as of the date of this news release and Mind Cure assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act of 1933 (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

SOURCE Mind Cure Health Inc.

For further information: Investor Relations: investors@mindcure.com; 1-888-593-8995

Posted on

Numinus Wellness Forges Forward into Psychedelic Discovery Research with the Orbitrap Exploris 120 Mass Spectometer

Acquisition of industry-leading instrument by Thermo Fisher Scientific will significantly advance psychedelic research and accelerate third-party standardized testing capabilities

VANCOUVER, BC, January 13, 2021 – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), is excited to announce it has acquired the Orbitrap Exploris 120 mass spectrometer with Vanquish Flex Binary (“Orbitrap”) instrument for its continued research and development of Psilocybe mushroom related projects at Numinus Bioscience, the Company’s 7,000 square foot analytics and research laboratory.

Implementation of the Orbitrap, a state-of-the-art high resolution mass spectrometry instrument, will continue the accelerated trajectory of Numinus Bioscience’s research strategy to optimize cultivation, harvest, and extraction of Psilocybe mushrooms. This follows Numinus’ successful completion of the first legal extraction in Canada by a public company for research and development purposes in December.

“Numinus continues to break ground in the research and development of psychedelic-assisted psychotherapies, and the implementation of the Orbitrap Exploris 120 mass spectrometer with Vanquish Flex Binary cements our role as the centre of excellence for psychedelic research and development,” said Sharan Sidhu, Science Officer and General Manager, Numinus. “As an early psychedelic substances license holder, this announcement demonstrates our commitment to staying at the forefront of psychedelic initiatives. Acquiring the Orbitrap is a fundamental step forward in developing Numinus Bioscience’s first patent, significantly advancing Psilocybe Mushroom related psychedelic discovery research and accelerating our third-party psychedelic standardized testing capabilities.”

Numinus Bioscience is focused on developing analytical methods and formulations for the evolving psychedelics space by establishing itself at the forefront of analytical testing for psychedelics. Use of the Orbitrap Exploris 120 will allow Numinus to accelerate psychedelic standardized testing, research and development activities for third-party clients and strategic partners, as well as high throughput testing for amenable compounds.

As well, the Orbitrap will be instrumental in ensuring that dried Psilocybe Mushrooms provided for special access are safe and that the therapeutic compounds consistently meet all required specifications. This follows Health Canada’s groundbreaking announcement of its intention to revise the Special Access Programme (SAP) to permit access to MDMA and psilocybin-assisted psychotherapy in the same way other investigational medications are accessed in Canada.

Health Canada’s Notice of Intent regarding the SAP will be open for public consultation and comments for the next 60 days, and Numinus strongly encourages the community to weigh in on the benefits of the revision. View the notice here: http://www.gazette.gc.ca/rp-pr/p1/2020/2020-12-12/html/notice-avis-eng.html#nb2.

To share comments and thoughts related to the SAP, please email hc.csd.regulatory.policy-politique.reglementaire.dsc.sc@canada.ca.

About Psychedelic-Assisted Psychotherapy

Psychedelic-assisted psychotherapy has gained a great deal of interest within the medical community and general public as research results demonstrate its superior effectiveness for a range of mental health conditions. These results are contributing to a paradigm shift in both the understanding and treatment of mental health conditions.

Numinus has announced plans to embark upon open-label compassionate access clinical trials of psilocybin-assisted psychotherapy for substance use disorders and MDMA-assisted psychotherapy for PTSD, enabling it to implement, test and refine optimal protocols for delivery before these therapies are widely accessible. This includes developing physical and human resource infrastructure more broadly to deliver psychedelic-assisted psychotherapy including for Special Access Programme patients.

Numinus is uniquely positioned to provide patients with MDMA and psilocybin-assisted psychotherapy under the expanded SAP revision based on its international partnerships and extensive work completed on developing safe and evidence-based protocols for psychedelic-assisted psychotherapy. The Company is also a leader in the industry as the first public entity in Canada to receive a licence to produce and extract psilocybin from mushrooms, the first to complete a legal harvest and extraction of Psilocybe mushrooms using this licence and the holder of a Health Canada dealer’s licence to import, export, possess, test and distribute MDMA, psilocybin and other psychedelics.

Applications for Numinus’s compassionate access trials and for access under the SAP, pending approval, are not yet open. To be advised of the status and procedures for applications when available, register for Numinus’s newsletter.

###

About Numinus

Numinus Wellness Inc. (TSXV: NUMI) is a mental health and wellness company creating an ecosystem of solutions centred around safe, evidence-based, accessible psychedelic-assisted psychotherapy to help people heal and be well.

Numinus Health is dedicated to delivering innovative treatments to address physical, mental, and emotional health, through clinics and virtual services.

Numinus R&D is conducting implementation science and leveraging partnerships to beta-test and refine optimal models of psychedelic-assisted psychotherapy delivery, setting the stage for approved routine use in mental health and wellness care.

Numinus Bioscience is focused on developing testing methods and effective formulas for the evolving psychedelics space. Health Canada licences, scientific expertise, and new technologies facilitate ongoing innovation, and high-throughput contract services generate established revenue.

Learn more at numinus.ca, and follow us on Facebook, Twitter, and Instagram.

Forward Looking Statements

This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licences and any inability to obtain all necessary governmental approvals licences and permits to operate and expand the Company’s facilities; regulatory or political change such as changes in applicable laws and regulations, including federal and provincial legalization, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; the Company’s limited operating history and lack of historical profits; reliance on management; the Company’s requirements for additional financing, and the effect of capital market conditions and other factors on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with research and development institutions, customers and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.

For further information:

Dana Harvey,

Chief Communications Officer,

Numinus Wellness Inc

media@numinus.ca

Posted on

Novamind Expands Psychedelic Medicine Access in Utah

Enhanced clinic enables greater access to ketamine and Spravato™ treatments

TORONTO, ON / ACCESSWIRE / January 13, 2021 / Novamind Inc. (CSE: NM) (“Novamind” or the “Company”), a mental health company specialized in psychedelic medicine, announces the expansion and optimization of its Cedar Psychiatry clinic in Layton, Utah (“Layton Clinic”), the largest clinic in the Company’s network.

The redesigned Layton Clinic now offers improved treatment rooms to accommodate a higher number of ketamine and Spravato™ (esketamine) treatments. The Layton Clinic expansion comes in response to a significant increase in demand for ketamine therapies across Novamind’s mental health clinics. In 2020 alone, the Cedar Psychiatry clinic network facilitated over 20,000 client visits, an increase of over 100 percent compared to the same period in 2019.

“The demand for mental health services continues to increase dramatically and we are responding by improving access to our most innovative treatments,” said Dr. Reid Robison, Chief Medical Officer and Director of Novamind. “The enhanced clinic layout enables us to serve more clients with evidence-based treatments, including ketamine and future FDA approved psychedelics.”

Cedar Psychiatry has gained years of experience in effectively managing the challenges associated with offering its clients access to novel medications such as Spravato™ and anticipated FDA-approved psychedelics. Cedar Psychiatry’s expertise includes inventory logistics, coordinating reimbursement with insurance providers and compliance with each medications’ unique Risk Evaluation and Mitigation Strategy (REMS).

“Enhancing service offerings at our Layton clinic goes to the heart of our mission, which is to increase our clients’ access to alternative mental health treatments,” said Yaron Conforti, CEO and Director of Novamind. “In 2021, Novamind will address the increasing demand for innovative mental health services by growing our network of Cedar Psychiatry clinics within Utah and into new jurisdictions.”

As a leading provider of ketamine therapy in the United States, Cedar Psychiatry has administered over 4,000 ketamine sessions and over 1,700 Spravato™ treatments since its founding in 2016. The Cedar Psychiatry clinic network has four locations in Utah, in Salt Lake City, Layton, Orem and Springville. For more information on the clinics, please visit our website.

About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly-owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Contact Information
Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Bill Mitoulas, Investor Relations
Email: bill@novamind.ca

Forward-Looking Statements
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

Posted on

Mind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin Therapy

The strategic partnership between Mind Cure and ATMA will bridge access to research locations for psychedelic drug research while providing patient data for iSTRYM, Mind Cure’s digital therapeutics platform.

VANCOUVER, BC, Jan. 12, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“Mind Cure” or the “Company”) is pleased to announce the signing of a non-binding letter of intent (the “LOI“) for strategic investment and commercial cooperation with ATMA Journey Centers Inc. (“ATMA“), a Calgary-based organization. ATMA is the first commercial treatment center in Canada to announce providing psychedelic-assisted therapy for a section 56 exempt patient. The LOI is intended to help Mind Cure secure an equity position within ATMA, empowering the Company with access to a global release strategy for iSTRYM, as well as international locations for translational research on novel molecules and treatment protocols.

“ATMA’s clinicians possess a proven track record of advocacy and innovation driving toward the therapeutic benefits of psychedelic medicine for patients in the treatment of mental health and wellness. Mind Cure is extremely excited to join ATMA in the renaissance  that is disrupting mental health care by partnering with one of the pioneers in the therapeutic psychedelics industry,” said Kelsey Ramsden, President & CEO, Mind Cure. “With Mind Cure’s therapeutic tool, iSTRYM, along with ATMA’s pivotal achievement as the care provider for Canada’s most recent section 56(1) exempt patient, mental health care in Canada is making history. We are thrilled to work with the best-in-class to drive our focus on accelerating our research and technology platforms.”

Mind Cure’s partnership with ATMA is an exciting opportunity for researchers and therapists to participate in each of Mind Cure’s research programs focused on pain, neuroregeneration, migraines, and cluster headaches. The proposed investment will facilitate the syndication of Mind Cure’s psychedelic drug protocols and the use of Mind Cure’s proprietary technology, iSTRYM, to optimize treatment for ATMA clients.

The deployment of capital will also advance speed and scale for data enrichment of iSTRYM, providing the AI-driven platform with access to patient data as ATMA targets domestic and international healing and treatment centers.

“Psilocybin-assisted therapy offers healing and understanding that is unmatched by traditional methods. Patients dealing with end-of-life anxiety, pain, depression, trauma, and addiction have been at the mercy of ineffective and underwhelming treatments for much too long. The resources are here, and we are extremely grateful to be at the frontlines of this world-changing, innovative, and extremely alleviating solution, to help bring peace to sufferers,” said David Harder, co-CEO, ATMA Journey Centers Inc. “We are witnessing an inflection point for mental health treatment as the commitment to wellness in Canada takes a huge step forward.”

Pursuant to the LOI, the parties intend to negotiate the terms of definitive agreements (the “Definitive Agreements“), which will provide for, among other things an initial $500,000 investment by Mind Cure in ATMA, participation by Mind Cure in ATMA’s future financings, and the exclusive use of iSTRYM throughout ATMA’s business. There can be no assurance that the Definitive Agreements will be entered into or that the investment or commercial transactions will be completed on the terms proposed in the LOI or at all.

About ATMA Journey Centers Inc. and SYNTAC Institute

ATMA is a private healthcare company with the mission of delivering effective and innovative healing and transformative experiences that awaken the inner healer and promote a deeper connection with the self, with others, and with the beauty of the world. ATMA is the first private sector service provider in Canada to announce psychedelic-assisted therapy provision under the approval of Health Canada’s Section 56(1) exemption, which will allow ATMA to provide psilocybin-assisted therapy to those seeking psychedelic assisted therapy.

ATMA’s founding members, David Harder, Greg Habstritt, and Vu Tran, also founded SYNTAC Institute, a non-profit organization with the mission of bringing the healing and transformative power of psychedelic medicine and psychedelic-assisted therapy to Canadians. SYNTAC has been an influential participant in the Canadian psychedelic medicine industry and operates Catalyst Presents, a series of conferences and summits in Canada focused on psychedelics.

About Mind Cure Health Inc.

Mind Cure exists as a response to the current mental health crisis and urgent calls for effective treatments. Mind Cure believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.

Mind Cure is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. Mind Cure is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information

Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: the conclusion of the transactions and negotiation of the Definitive Agreements contemplated by the LOI on the terms disclosed herein, or at all; ATMA conducting additional psychedelic-assisted therapy; the disruption of mental health care through psychedelic-based therapies; the development of iSTRYM and incorporation into ATMA’s business; the relationship with ATMA accelerating the development of Mind Cure’s research and technology platforms; participation of researchers and therapists in Mind Cure’s research programs; Mind Cure’s investment facilitating the syndication of Mind Cure’s psychedelic drug protocols and the development of those protocols; protocols and iSTRYM to optimize treatment for ATMA clients and driving greater access to patient data for the AI-driven digital therapeutics platform; the roll-out of domestic and international treatment centres by ATMA; the realization of an inflexion point for mental health treatment; and Mind Cure’s collection of data from ATMA’s section 56 exempt clients.

Forward-looking information is based on a number of key expectations and assumptions made by Mind Cure, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and Mind Cure’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect Mind Cure’s business; there will be a demand for Mind Cure’s products and ATMA’s clinics in the future; no unanticipated expenses or costs arise; Mind Cure will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; the partnership with ATMA will help Mind Cure achieve its business goals; and Mind Cure will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what Mind Cure believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, Mind Cure’s industry and Mind Cure’s business, which may negatively impact, and may continue to negatively impact, Mind Cure and may materially adversely affect Mind Cure’s investments, results of operations, financial condition, and Mind Cure’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; Mind Cure’s partnership with ATMA may not help Mind Cure achieve its business goals; iSTRYM, and its database function may not be successfully developed or help to optimize protocols and enhance scientific research; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect Mind Cure can be found under “Risk Factors” in Mind Cure’s final prospectus which is available on SEDAR at www.sedar.com.

The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to Mind Cure. The forward-looking information is stated as of the date of this news release and Mind Cure assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Mind Cure Health Inc.

For further information: Investor Relations: investors@mindcure.com 1-888-593-8995

Posted on

Will psychedelic mushroom vacations come to the U. S.?

The palm-fringed beachfront and breezy cabanas at MycoMeditations are the stuff of glossy travel brochures, but the barefoot vacationers roaming the Jamaican retreat center this winter are seeking a different kind of trip entirely.

They’re here for facilitated sessions using psychedelic psilocybin mushrooms. One of a handful of established psilocybin retreat centers in the world, MycoMeditations was founded in 2015, and in the years since has seen surging interest in the reputed mental health benefits of psychedelics. Often, it’s from people surprised to find themselves seeking help from a mysterious fungus at all.

“In my life I had never done any psychedelic,” said Jessica Young, a 41-year-old executive from Atlanta, who flew to Jamaica for a MycoMeditations retreat in November 2019. “It’s pretty out of character for me.”

Like many Americans unfamiliar with crystal magic or jam band music, Young knew little about psychedelics before reading the best-selling 2018 book “How to Change Your Mind,” by journalist Michael Pollan.

In it, Pollan surveys recent research into psychedelics, which show promise for maladies from treatment-resistant depression to end-of-life distress. Such professorial passages alternate with Pollan’s eyebrow-raising personal experiences with psychedelics including psilocybin, LSD and the crystallized venom of a Sonoran Desert toad.

Young had just turned 40 when she read the book, and she was intrigued by the promise of personal growth that psilocybin seemed to offer. But despite the relative mainstreaming of psychedelics in recent years, psilocybin mushrooms are ranked alongside heroin as a Schedule 1 drug in the United States. To try them legally — an important stipulation for Young — she would have to look abroad.

“Psilocybin is not illegal here, and it’s one of the few places in the world where you can actually use these substances,” said Justin Townsend, MycoMeditations’ CEO and head facilitator. (The Netherlands, where a legal loophole allows for the sale of psilocybin sclerotia, or “truffles,” is another major destination.)

But over recent months, decriminalization efforts have opened a chink in the United States’ forbidding drug laws. In November, D.C. voters approved a ballot initiative to decriminalize the use of psilocybin mushrooms, while Oregonians approved the legal use of psilocybin in therapeutic settings. If restrictions continue to loosen, could stateside psychedelic getaways be America’s next big wellness-
travel trend?

Demand is there. Each month, the inbox of researcher Robin Carhart-Harris fills with requests, sometimes pleas, to join clinical trials at the Centre for Psychedelic Research that he heads at Imperial College London.

When it comes to the healing power of psychedelics, “demand vastly exceeds supply,” Carhart-Harris said. “They’re suffering, and they’re desperate, and other treatments maybe aren’t working.” When it launched in 2019, the center became the world’s first formal site focusing exclusively on psychedelic research; later that same year, Johns Hopkins opened the Center for Psychedelic and Consciousness Research.

Promising findings about psychedelics include treatments for trauma, anorexia, treatment-
resistant depression, addiction and more. Many of those who contact Carhart-Harris in hopes of joining a clinical study are suffering from these. “Often it’s really sad,” he said. “A few a day is typical, and we can’t do anything.”

Mushroom capsules at MycoMeditations. Last year, U.S. News & World Report speculated that psilocybin could beat out cannabis as a hot investment. (Abbie Townsend)

Retreats step into the void between the swelling interest in psychedelic therapy and the tightly controlled trials carried out at the new research centers. And those retreats run a remarkable gamut. Some employ the language, tone and sleekly modern aesthetic of upscale clinics; others are crunchy, off-grid hippie getaways with training lineages rooted in shamanism.

Carhart-Harris’s research has convinced him that psychedelics can facilitate profound transformations, and he’s optimistic about their use beyond the lab. When compared with other drugs — or even alcohol — psilocybin is remarkably safe. It’s not addictive, and toxicity is very low.

In 2018, Carhart-Harris and a team of other researchers published survey results focused on psychedelic experiences “in the wild” — people who got their own stash of drugs and launched into orbit without supervision from a PhD. Overall, respondents did well. “That aggregate data is tending toward improvement,” Carhart-Harris said. “Any negative changes in mental health outcomes are very much the anomaly.”

In addition to offering legal alternatives to an at-home trip, retreats provide support, with the possibility of post-trip counseling to help with “integration,” a meaning-making process many believe is essential. But Carhart-Harris also sees pitfalls in the drugs’ very promise. “It’s easy to see how powerful they are,” he said. “It’s unusual to find drugs, or any intervention, that could change people as reliably. That power requires some responsibility and careful thought around harnessing it safely.”

Writer Michelle Janikian, author of the 2019 book “Your Psilocybin Mushroom Companion,” has volunteered at and participated in magic-mushroom retreats, and echoed Carhart-Harris’s caution. “Folks need to research their retreat leaders,” she said. “Do your homework first to make sure it’s a safe and integral place.”

But Janikian, like many in the world of psychedelics, welcomes the nascent push to legalize and decriminalize psilocybin in the United States. “I’m very excited to see how it continues to go — I think the recent passage in Oregon is going to have kind of a ripple effect.”

Michelle Janikian’s “Your Psilocybin Mushroom Companion,” a guide published in November of 2019. (Ulysses Press)

And many in the investor class see a bright future for magic mushrooms. In September, U.S. News & World Report speculated that psilocybin could beat out cannabis as a hot investment, citing a market analysis estimating the psilocybin market may grow to $100 billion.

Retreats could be part of that growth. Within days of the Oregon vote to legalize psilocybin use in therapeutic settings, Oregon-based Silo Wellness — which cultivates psychedelic mushrooms in Jamaica — announced an Oregon wellness retreat using the drug ketamine. For five socially distanced days in January, a small group will explore waterfalls, go white-water rafting, meditate and undergo three sessions of ketamine-assisted therapy led by naturopath Matthew Hicks.

Silo Wellness founder Mike Arnold described the ketamine sessions as the first legal psychedelic retreat to take place in the United States. (There’s a long-running underground of unsanctioned psychedelic retreats across the country.) Next, he’s planning psilocybin retreats in Jamaica and hopes that soon they’ll be taking place closer to home. Arnold, who would like to see the state become a psychedelic retreat destination, is staking his company on psilocybin’s potential to expand both markets and minds.

What will that mean for Americans? For Young, who traveled to Jamaica in 2019, the experience was transformative.

While she worried she would find a bunch of partying bros, her 2019 retreat was anything but. Instead, she was part of an ­11-person cohort that included six women, more than one grandmother, medical and mental health professionals, scientists and a construction worker.

“Everyone was there with the intention to do some serious work,” Young said. So was she: Over three psilocybin sessions, Young said she grew in ways that years of therapy hadn’t achieved. In November 2020, she returned for a second retreat.

“I came out of that with this very deep knowing that this life force that’s all around us — what I would call love, essentially — is abundant, is ever present,” Young said. “I know that sounds like it comes from a pack of tarot cards. But for me, it’s profound.”

Smith is a writer based in Vermont. Her website is jenrosesmith.com. Find her on Twitter and Instagram @jenrosesmithvt.

Posted on

Mind Cure Announces Build-Out of Digital Therapeutics, iSTRYM: A Technology Platform for Mental Wellness Optimization & Psychedelic Research

Mind Cure’s iSTRYM (pronounced eye-stream) has been designed to warehouse the largest collection of psychedelic research and ongoing mental optimization data. With machine learning deployed, iSTRYM will provide greater speed to Mind Cure’s research team, richer data to health professionals and clients, as well as a hub of protocol and procedural information for psychedelic practitioners worldwide.

VANCOUVER, BC, Jan. 06, 2021 – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“Mind Cure” or the “Company”) is pleased to announce the release of iSTRYM, the Company’s digital therapeutic tool, designed to provide close to real-time data regarding patient care, procedures and protocols, and other resources for therapists, clinicians, and patients with mental health concerns.

“As a life sciences and digital therapeutics company, providing speed to market with novel psychedelic therapies through deeper data analytics is a strength we are developing with iSTRYM. Further, as we build out our database for mental wellness, both therapists and individuals will get mental wellness protocols for wellness optimization and support. iSTRYM exists to become the source that individuals turn to for science-backed, personalized mental health support at scale.”– Kelsey Ramsden, President & CEO.

Gaps between clients, researchers, and therapists create disparities in the collection of critical insights that arise outside of psychedelic-assisted therapy sessions, and ultimately prevent new scientific breakthroughs. Mind Cure’s iSTRYM provides a digital solution to the loss of crucial, uncategorized data points by connecting patient feedback and clinician expertise together in one place. Additionally, most psychedelic therapy research exists in cloistered scientific communities, which limits the possible intersection of great clinical practice and new protocols. iSTRYM brings together a large database of existing protocols to all psychedelic clinicians, enhancing the scientific efficacy for the entire psychedelic research community.

“We’re developing the kind of global administration portal that could become the solution the industry needs. One of the key differentiators in our proprietary tech piece is the implementation of artificial intelligence, working in the background, to taxonify the uncategorized daily inputs from patients into tangible assets that will then inform treatments. From onboarding patients to collecting critical insights across different arms of the psychedelics research space, iSTRYM could revolutionize the way we build communities around a common goal of mental wellness.” – Geoff Belair, CTO.

About Mind Cure’s iSTRYM

iSTRYM is a centralized management system for psychedelic therapeutic research, the deployment of care and integration based on a microservices design model, and is built with responsive principals. iSTRYM contains strategic data loops that continually aggregate new insights, and an application that equips patients as active participants in their own mental wellness journey.

The focus with iSTRYM is to disrupt the mental health industry by providing accessible and innovative technological resources that optimize the use of patient data to support diagnoses and treatments. iSTRYM’s app component will record patients’ uncategorized data, such as weather, location, mood, heart rate, and other metrics that take place after therapy sessions and throughout therapeutic integration.

This protocol optimization coupled with iSTRYM’s AI will create a convergence of commonalities among patients. iSTRYM will use AI to collate insights found across datasets to steer clinicians towards better diagnoses, treatments, and ultimately personalized care at scale.

The name iSTRYM reflects empathy, commonalities, and Mind Cure’s mission as an adaptive mental wellness company. The lowercase “i” represents the collective “we” of humanity and life on planet Earth, all of which are connecting, building, and reflecting together as pillars in our world. As a stream flows, adapts, grows, and changes, so do we. We choose to work collectively, utilizing data to elevate and transform our collective mental wellness.

About Geoff Belair

Geoff Belair, Mind Cure’s Chief Technology Officer, has over 30 years of experience leading as a senior architect of innovative technology platforms that require precise, secure integrations. Geoff managed the development of technology solutions in the fintech, banking, and insurance industries. He possesses a unique combination of software architecture and design experience with a deep understanding of technology adoption, with platforms that have exceeded $1 billion in annual activity across 125ᐩ locations. His experience with security infrastructure and agile methodologies ensures technical foundations are scalable in every project he leads.

About Mind Cure Health Inc.

Mind Cure exists as a response to the current mental health crisis and urgent calls for effective treatments. Mind Cure believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.

Mind Cure is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. Mind Cure is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

On Behalf of the Board of Directors

Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information
Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: iSTRYMS’ close to real time data regarding patient care, procedures and protocols, and other resources to therapists, clinicians, and patients of mental health concerns; iSTRYMS’ ability to optimize clinical research; iSTRYMS’ ability to connect a large database of existing protocols to all psychedelic clinicians, enhancing the scientific efficacy for the entire psychedelic research community; iSTRYMS’ ability to disrupt the mental health industry by providing accessible and innovative technological resources that optimize the use of patient data to support diagnoses and treatments; iSTRYMS’ app’s ability to record uncategorized data; and iSTRYMS’ AI’s ability to collate patient-data.

Forward-looking information is based on a number of key expectations and assumptions made by Mind Cure, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and Mind Cure’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect Mind Cure’s business; there will be a demand for Mind Cure’s products in the future; no unanticipated expenses or costs arise; Mind Cure will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; that Mind Cure’s proprietary technology, iSTRYM, and its database function will be able to effectively optimize protocols and enhance scientific efficacy via patient-led feedback and will continue to grow; and Mind Cure will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what Mind Cure believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, Mind Cure’s industry and Mind Cure’s business, which may negatively impact, and may continue to negatively impact, Mind Cure and may materially adversely affect Mind Cure’s investments, results of operations, financial condition, and Mind Cure’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; Mind Cure’s proprietary technology, iSTRYM, and its database function may not help to optimize protocols and enhance scientific research and may not be able to grow; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect Mind Cure can be found under “Risk Factors” in Mind Cure’s final prospectus which is available on SEDAR at www.sedar.com.

The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to Mind Cure. The forward-looking information is stated as of the date of this news release and Mind Cure assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Mind Cure Health Inc.

Connect: Investor Relations: investors@mindcure.com; 1-888-593-8995

Posted on

Numinus Signs Lab Services Agreement with Optimi Health to Advance Research and Development of Psychedelic Products

The agreement will focus on developing safe, effective, all-natural products for the emerging psychedelic industry

VANCOUVER, BC, January 6, 2021 – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), announced today that it has signed a lab services agreement with Optimi Health Corp. (“Optimi”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, to further the research and development of Canadian-grown psilocybin-producing mushrooms.

Through this first-of-its-kind agreement, Optimi will utilize and leverage Numinus Bioscience’s laboratories, equipment, services and expertise, with the goal of developing products for the emerging psychedelic industry. Optimi has applied to Health Canada for a research exemption allowing it to conduct activities involving psychedelic compounds and, in advance of approval, will undertake a number of research and development projects with Numinus related to Psilocybe mushrooms, psychedelic compounds, and formulations.

“We’re excited to partner with Optimi and its highly experienced and passionate team to advance psychedelic initiatives and develop safe and effective products,” said Payton Nyquvest, CEO, Founder and Chairman, Numinus. “Demand for natural products that optimize mental health and performance continues to grow, and we see great potential in psilocybin-producing mushroom products to provide these benefits. We look forward to working with Optimi to advance development in this rapidly expanding marketplace.”

“Numinus is an ideal partner to further our research and development of Psilocybe mushroom and associated derivatives-based products,” said Mike Stier, CEO, Optimi Health Corp. “Numinus’ state-of-the art laboratory, specialized equipment and second-to-none expertise in psychedelic research will be critical to developing the safe, effective, all-natural products that we believe to be the flagship products in this space.”

Under the terms of the agreement, Optimi will pay an initial retainer with fees for services determined and replenished on a project-by-project basis. Each project is expected to be a stand-alone project that is defined by a Statement of Work, and while certain projects may build upon previously completed ones, there may also be several projects undertaken at the same time. Optimi will further issue to Numinus 150,000 fully paid and non-assessable common shares in the capital of Optimi (each a “Share”) on January 4, 2021 and 150,000 Shares upon completing the first project that the parties enter into. All shares will be subject to resale restrictions expiring four months and one day from their date of issue.

Numinus Bioscience’s laboratory provides services including cultivation, analytical testing, product research and development, and ancillary services in the area of psychedelics. The agreement with Optimi, is effective January 4, 2021 and constitutes one of the first opportunities for Numinus to generate revenue from independent parties utilizing our state of the art laboratory facility, scientific expertise and authorization to work with controlled drugs and substances.

###

 

About Numinus

Numinus Wellness Inc. (TSXV: NUMI) is a mental health and wellness company creating an ecosystem of solutions centred around safe, evidence-based, accessible psychedelic-assisted psychotherapy to help people heal and be well.

Numinus Health is dedicated to delivering innovative treatments to address physical, mental, and emotional health, through clinics and virtual services.

Numinus R&D is conducting implementation science and leveraging partnerships to beta-test and refine optimal models of psychedelic-assisted psychotherapy delivery, setting the stage for approved routine use in mental health and wellness care.

Numinus Bioscience is focused on developing testing methods and effective formulas for the evolving psychedelics space. Health Canada licences, scientific expertise, and new technologies facilitate ongoing innovation, and high-throughput contract services generate established revenue.

Learn more at numinus.ca, and follow us on Facebook, Twitter, and Instagram.

About Optimi Health

Optimi Health is developing a vertically integrated Canadian functional mushroom brand that focuses on the health and wellness sector. The Company intends to cultivate, extract, process and distribute high quality strains of fungi products in its facility located in Princeton, British Columbia. Optimi intends to grow and process functional mushrooms in order to develop and sell its mushrooms and related health food products directly to consumers, and to other health food brands and distributors.

Find out more at optimihealth.ca

Forward Looking Statements

This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licences and any inability to obtain all necessary governmental approvals licences and permits to operate and expand the Company’s facilities; regulatory or political change such as changes in applicable laws and regulations, including federal and provincial legalization, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; the Company’s limited operating history and lack of historical profits; reliance on management; the Company’s requirements for additional financing, and the effect of capital market conditions and other factors on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with research and development institutions, customers and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.

For further information:

Dana Harvey,

Chief Communications Officer,

Numinus Wellness Inc

media@numinus.ca

Posted on

Tonic Magazine

Using Psychedelics To Treat Addictions

5 Questions About The DMT Molecule

Jamie Bussin and Timothy Ko

In Episode #162 of THE TONIC Talk Show,  the CEO of Entheon Biomedical spoke about the efficacies of treating addictions with stabilized DMT molecules. This is an excerpt from that interview. The full interview can be found at www.thetonic.ca

I think what’s driving this is the faults within the current medical system’s treatment of substance use and abuse. Our work addresses the limitations of the current medicalized treatment model for treating substance disorder. Societally we’re all bearing witness to those failures. In Vancouver alone, we have overdose deaths at a rate of 120 to 180 persons per month. Drug addictions and substance disorders tear at the fabric of society at every imaginable level. Hospital costs and policing is a drain. On a personal level it’s destructive to individuals and their families. All of the conventional models of treatments are extremely low on the efficacy rates,  as low as 5 to 10%. Stand-alone treatments for individuals can cost from $5,000 to $30,000;  some drug users will have 6 drug treatment stents in their life – often resulting in death.

Your company, Entheon, is taking a different approach. What is that? Trying to stabilize the patient with a variety of things. Whether it’s medication such as antidepressants, antipsychotics and psychedelics, so that they can do some introspective work such as psychotherapy, a 12 step-like therapy, with a view to assessing their internal make up, what their barriers are, what their catchments are so that they can rework that and get to a place of meaningful reformation of their internal characteristics and from there their behaviors will change. But the reality is that for a lot of drug abusers there is this intractable trauma that makes conventional methods difficult. As you delve deeper into their core truths, the trauma patients tend to retreat even further even into dissociation. We understand with psychedelics, that really key component of creating profound introspection, that epiphanic unearthing of core truths can’t just be delivered without context of a psychotherapy environment. We’re creating that network of support that precedes and follows the psychedelic experience to help optimize integration of that experience so the individual can have some consolidation, recontextualizing who they are, their belief systems, what motivates them and breaking through their traumatic barriers so they can have different behaviours, that aren’t driven by pain or fear.

Why are you using the DMT molecule for this purpose? DMT is the active ingredient in Ayahuasca – a psychoactive “jungle brew” employed generally in South American cultures to treat “diseases of despair” – the existential feeling of being lost. The Ayahuasca experience creates this massively profound introspective journey where the individual will have these deeply personal experiences. One of the limitations of Ayahuasca is that it is very difficult to create repeatable, precise doses for medical purposes. We’re taking a purely synthetic version of DMT and administering it in a safe, gradual and precise way that is controllable by a physician. The Ayahuasca experience can take 6-12 hours during which the individual may have an overwhelmingly difficult situation they may not be prepared for – there is no “off switch”. Whereas our approach is via a regulated intravenous pump. If the experience gets too intense, we can modulate the dosing or even stop it altogether, with a return to baseline functions within 15-20 minutes. The patients arrive at that therapeutic place gradually. We’re using the right molecules delivered in the right way so that we can create a very customized, safe experience.

Explain a little bit about the regulatory process you’ve gone through.  Even though psychedelics are in a unique space, novel in some regards, the reality is that the population that we’re trying to help are medicalized. They have medical disorders. The traditional drug discovery pathway that exists for other pharmaceutical companies exists for us too.  So we’re engaged in all the necessary clinical trial steps and we’re engaging all the necessary regulators like Health Canada, the FDA and the European agency when appropriate. We have signed our clinical trials agreement with our research partner in the Netherlands. We also have our GMP production agreement signed. We anticipate having all the pieces in place for human clinical trials in Q3 or Q4.

I understand that the work Entheon is doing is very personal for you. Everyone has probably been affected by knowing someone with addictions. My story is no different. My brother was a longtime drug user, since the age of 17. He suffered a traumatic event in his teens, and his way of coping was to take up drugs. Initially it started pretty innocently. But over the course of two decades that drug use did escalate to being highly problematic and apparent and involved over 8 treatment attempts. He was medicated. He spent hundreds if not thousands of hours with therapists. For two years I was responsible for overseeing my brother’s care. I saw well intentioned professionals earnestly trying to help my brother, but he slipped further into a state of dissociation and we lost him eventually. I’ve used DMT and have undergone psychotherapy to help me work through my own traumatic issues relating to my family of origin and my relationship with my brother and my father – issues woven into the fabric of who I was. DMT really did help me reformat my understanding of my attachments and resentments, my outlook on life. I was teetering on the edge of something very dark and I’m so lucky that I found out what was on the other side of that.

For more information about Timothy Ko and his work at Entheon Biomedical please visit entheonbiomedical.com